Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

NCT05346601 | Completed Phase 1 DMC

• 1 other identifier: CAR 108
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to further study the pharmacokinetic characteristics of Chiauranib Capsule in Healthy Volunteers with High Fat Diet.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (3)

• Pharmacokinetics of Chiauranib (in plasma)

  Peak plasma concentration for Chiauranib(Cmax)

  up to 20 Days

• Pharmacokinetics of Chiauranib (in plasma)

  Area under the concentration-time curve from zero to last quantificable concentration for Chiauranib (AUC0-t)

  up to 20 Days

• Pharmacokinetics of Chiauranib (in plasma)

  Area under the concentration-time curve from zero extrapolated to infinity for Chiauranib（AUC0-inf）

  up to 20 Days

Secondary Outcomes (5)

• Pharmacokinetics of Chiauranib (in plasma)

  up to 20 Days

• Pharmacokinetics of Chiauranib (in plasma)

  up to 20 Days

• Pharmacokinetics of Chiauranib (in plasma)

  up to 20 Days

• Pharmacokinetics of Chiauranib (in plasma)

  up to 20 Days

• Pharmacokinetics of Chiauranib (in plasma)

  up to 20 Days

Study Arms (2)

Chiauranib(In the fasting state)

OTHER

Experimental: Chiauranib Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet

Drug: Chiauranib

Chiauranib(In the high fat diet state)

OTHER

Experimental: Chiauranib Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state

Drug: Chiauranib

Interventions

Chiauranib DRUG

50mg po only once

Chiauranib(In the fasting state); Chiauranib(In the high fat diet state)

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Ages: 18 Years to 45 Years
• ≤BMI≤26. Weight of male ≥50 kg and Weight of female 45 kg
• at screening Healthy or NCS as determined by the Investigator based on physical examination, vital signs, a series of laboratory examinations（such as blood routine examination, et.al）and 12-lead electrocardiogram (ECG)
• Healthy Volunteers have no plan to fertilize throughout treatment and for at least 6 months after study is stopped
• Healthy Volunteers voluntarily sign informed consent
• Able to communicate well with the Investigator, to comply with the requirements of the study

You may not qualify if:

• Has known allegies to Chiauranib ,any of the excipients or Have a history of relevant atopy or drug hypersensitivity
• Being hypertension or having risk of hypertension, or SBP≥140 mmHg, DBP ≥90 mmHg; or Being hypotension or having risk of hypotension, or SBP \< 90 mmHg, DBP \< 60 mmHg
• Inability to take oral medication or having Gastrointestinal, liver and kidney diseases that affect drug absorption or metabolism within 6 months
• Prior to random Having uncured diarrhea or having 4 or more episodes of diarrhea within 7 days prior to scheduled drug administration
• Having any significant history of hemorrhagic disease or any history of coagulopathy
• A history of frequent and severe infection(≥3 episodes)within the past 1 year, or a history of severe infection within 3 months prior to drug administration；
• Ccr \< 80 mL/min
• Difficulty of venous blood collection
• QTcF \> 450 ms
• Drug abuse within 5 years or used drug within 3 months prior to the study, or Urine drug screening is positive during screening
• Heavy smokers(average daily smoking of more than 5 cigarettes/ day during past 3 months prior to screenig); heavy drinkers(average weekly drinking of more than 14 units of alcohol during past 6 months prior to screening, 1 unit =360 mL beer or 45 mL 40% spirits or 150 mL wine); Having Alcoholic products within 2 days prior to drug administration, or Alcohol breath test result ≥20 mg/dl
• Ingestion of prescription drugs, OTC drug, Vitamin, dietary supplements or herbal products within 14 days prior to screening
• Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism(CYP3A, CYP1A2 and CYP2D6)within 30 days prior to drug administration of the study medication, or Subjects who have taken any foods and drinks known to induce or inhibit hepatic drug metabolism within 7 days prior to drug administration
• Intake of Tea, Coffee or other Caffeinated beverage(more than 8 cups, 1 cup=250 mL)within 14 days prior to drug administration, Intake of any food or beverage containing or metabolized to produce caffeine or xanthine within 48 hours prior to drug administration
• Subjects with clinically relevant evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication

Sponsors & Collaborators

• Chipscreen Biosciences, Ltd.: lead
• H & J CRO International, Inc.: collaborator

Study Sites (1)

The First Affiliated Hospital of Suzhou University

Suzhou, Jiangsu, 21500, China

Location

MeSH Terms

Interventions

chiauranib

Study Officials

• LiYan Miao

  First Affiliated Hospital of Suzhou Medical College

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2022
• First Posted: April 26, 2022
• Study Start: June 2, 2022
• Primary Completion: June 28, 2022
• Study Completion: June 28, 2022
• Last Updated: February 9, 2023

Record last verified: 2023-02

Locations

CN (1)